Amitryptyline HCI Tablets IP

Amitryptyline HCI tablets IP is recommended for patients suffering from neuropathic pain, major depressive disorder and attention deficit hyperactivity disorder.  These tablets contain active compound (C20H23N)  that has 277.403 g/mol molecular weight. This compound is present in 30% to 60% amount. It metabolizes in liver in presence of CYP2C9 gene. This gene has around 96% protein binding capacity. As tricyclic antidepressants, Amitryptyline HCI tablets IP influence activities of serotonin hormone. After taking these tablets, these are quickly absorbed from gastrointestinal tract and are metabolized in liver in presence of CYP2C19 and CYP2D6 enzymes.

Provided tablets are recommended for patients of neuropathic pain (caused by damages in nerves) and depression.

These tablets raise the level of chemical messenger in nerves to control mood during treatment of depression.

Difficulty in urination, dry mouth, blurred vision, sleepiness, orthostatic hypotension (sudden fall of blood pressure while standing), weight gain, constipation, raise in heart beat.